Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs

Bae, Ki Hyun; Lee, Fan; Xu, Keming; Keng, Choong Tat; Tan, Sue Yee; Tan, Yee Joo; Chen, Yi‐Ping Phoebe; Kurisawa, Motoichi

doi:10.1016/j.biomaterials.2015.06.008

Cited by 54 publications

(44 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The thickness of the fibrous capsule was comparable to that of capsule induced by biocompatible materials reported in literature [32]. In addition, these results are in good agreement with recent reports on the minimal capsule formation observed from the tissues of mice implanted with enzymatically-crosslinked dextran-Tyr/PEG hydrogels [33]. For HA-Tyr-TZB-5, we did not observe any hydrogel remaining at the injection site at both day 14 and 28, indicating the total degradation of HA-Tyr-TZB-5 within two weeks.…”

Section: In Vivo Degradation and Tissue Reaction Of Ha-tyr Hydrogelssupporting

confidence: 93%

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

Lee

Gao

et al. 2015

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

Section: In Vivo Degradation and Tissue Reaction Of Ha-tyr Hydrogelssupporting

confidence: 93%

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

Lee

Gao

et al. 2015

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

“…[31] Thus, we set out to determine the bioactivity of FGF-2 after encapsulation and release from hydrogels following well-established protocols, [32] specifically examining the effect of released components on AF proliferation. Hydrogels containing FGF-2 were suspended in reducing and non-reducing microenvironments at 4°C (to minimize protein degradation); after 7 days, the supernatant was lyophilized and reconstituted at a concentration of 1 ng/mL FGF-2 in stromal cell basal medium (SCBM) containing 5% stripped serum.…”

Section: Resultsmentioning

confidence: 99%

Controlling the Release of Small, Bioactive Proteins via Dual Mechanisms with Therapeutic Potential

Kharkar

Scott

Olney

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Injectable drug delivery systems that respond to biologically relevant stimuli present an attractive strategy for tailorable drug delivery. Here, we report the design and synthesis of unique polymers for the creation of hydrogels that are formed in situ and degrade in response to clinically relevant endogenous and exogenous stimuli, specifically reducing microenvironments and externally applied light. Hydrogels were formed with polyethylene glycol and heparin-based polymers using a Michael-type addition reaction. The resulting hydrogels were investigated for the local controlled release of low molecular weight proteins (e.g., growth factors and cytokines), which are of interest for regulating various cellular functions and fates in vivo yet remain difficult to deliver. Incorporation of reduction-sensitive linkages and light-degradable linkages afforded significant changes in the release profiles of fibroblast growth factor-2 (FGF-2) in the presence of the reducing agent glutathione or light, respectively. The bioactivity of the released FGF-2 was comparable to pristine FGF-2, indicating the ability of these hydrogels to retain the bioactivity of cargo molecules during encapsulation and release. Further, in vivo studies demonstrated degradation-mediated release of FGF-2. Overall, our studies demonstrate the potential of these unique stimuli-responsive chemistries for controlling the local release of low molecular weight proteins in response to clinically relevant stimuli.

show abstract

“…It has been shown that these new humanized mice could be infected with human strains of hepatitis viruses and exhibit leukocyte infiltrations, liver inflammation, fibrosis, cirrhosis, and elevated cytokines similar to HCV-infected patients (Bility et al 2014; Keng et al 2015; Tan-Garcia et al 2017; Washburn et al 2011). Mouse models with human liver cells and matched human immune system provides an important platform for understanding disease pathogenesis of hepatitis viruses through human-specific cytokines, chemokines and immune cell regulations involved, potentially translating this knowledge into creation of anti-fibrotic and immune-modulatory therapeutics (Bae et al 2015; Keng et al 2015). …”

Section: Models Of Human Diseases Established On Humanized Micementioning

confidence: 99%

Humanized Mice as Unique Tools for Human-Specific Studies

Yong

Her

Chen

2018

Arch. Immunol. Ther. Exp.

Self Cite

View full text Add to dashboard Cite

With an increasing human population, medical research is pushed to progress into an era of precision therapy. Humanized mice are at the very heart of this new forefront where it is acutely required to decipher human-specific disease pathogenesis and test an array of novel therapeutics. In this review, “humanized” mice are defined as immunodeficient mouse engrafted with functional human biological systems. Over the past decade, researchers have been conscientiously making improvements on the development of humanized mice as a model to closely recapitulate disease pathogenesis and drug mechanisms in humans. Currently, literature is rife with descriptions of novel and innovative humanized mouse models that hold a significant promise to become a panacea for drug innovations to treat and control conditions such as infectious disease and cancer. This review will focus on the background of humanized mice, diseases, and human-specific therapeutics tested on this platform as well as solutions to improve humanized mice for future clinical use.

show abstract

Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs

Cited by 54 publications

References 53 publications

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

Controlling the Release of Small, Bioactive Proteins via Dual Mechanisms with Therapeutic Potential

Humanized Mice as Unique Tools for Human-Specific Studies

Contact Info

Product

Resources

About